199 related articles for article (PubMed ID: 30056975)
1. Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions.
Castinetti F; Albarel F; Archambeaud F; Bertherat J; Bouillet B; Buffier P; Briet C; Cariou B; Caron P; Chabre O; Chanson P; Cortet C; Do Cao C; Drui D; Haissaguerre M; Hescot S; Illouz F; Kuhn E; Lahlou N; Merlen E; Raverot V; Smati S; Verges B; Borson-Chazot F
Ann Endocrinol (Paris); 2018 Oct; 79(5):591-595. PubMed ID: 30056975
[TBL] [Abstract][Full Text] [Related]
2. Introduction to expert opinion on endocrine complications of new anticancer therapies.
Castinetti F; Borson-Chazot F
Ann Endocrinol (Paris); 2018 Oct; 79(5):535-538. PubMed ID: 30056976
[TBL] [Abstract][Full Text] [Related]
3. French Endocrine Society Guidance on endocrine side effects of immunotherapy.
Castinetti F; Albarel F; Archambeaud F; Bertherat J; Bouillet B; Buffier P; Briet C; Cariou B; Caron P; Chabre O; Chanson P; Cortet C; Do Cao C; Drui D; Haissaguerre M; Hescot S; Illouz F; Kuhn E; Lahlou N; Merlen E; Raverot V; Smati S; Verges B; Borson-Chazot F
Endocr Relat Cancer; 2019 Feb; 26(2):G1-G18. PubMed ID: 30400055
[TBL] [Abstract][Full Text] [Related]
4. Expert opinions on endocrine toxicity induced by new anticancer therapies: Precautions to be taken in performing and interpreting hormonal assays under immunotherapy.
Lahlou N; Raverot V
Ann Endocrinol (Paris); 2018 Oct; 79(5):550-554. PubMed ID: 30149892
[TBL] [Abstract][Full Text] [Related]
5. Management of Immune-Related Endocrinopathies in Anticancer Treatment with Checkpoint Inhibitors.
Lakomý R; Poprach A; Kazda T
Klin Onkol; 2020; 33(1):15-19. PubMed ID: 32075383
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy-induced endocrinopathies: Insights from the 2018 French Endocrine Society Guidelines].
Castinetti F; Borson-Chazot F
Bull Cancer; 2019 May; 106(5):492-496. PubMed ID: 30981462
[TBL] [Abstract][Full Text] [Related]
7. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.
Joshi MN; Whitelaw BC; Palomar MT; Wu Y; Carroll PV
Clin Endocrinol (Oxf); 2016 Sep; 85(3):331-9. PubMed ID: 26998595
[TBL] [Abstract][Full Text] [Related]
9. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach.
Iglesias P
Eur J Intern Med; 2018 Jan; 47():6-13. PubMed ID: 28826822
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor therapy-induced hypophysitis ∼ a case series of Taiwanese patients.
Lin CH; Chen KH; Chen KY; Shih SR; Lu JY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):524-529. PubMed ID: 30104119
[TBL] [Abstract][Full Text] [Related]
12. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review.
Gebauer J; Higham C; Langer T; Denzer C; Brabant G
Endocr Rev; 2019 Jun; 40(3):711-767. PubMed ID: 30476004
[TBL] [Abstract][Full Text] [Related]
14. [Endocrinopathies induced by immune checkpoint inhibitors].
Jaafar J; Mavromati M; Philippe J
Rev Med Suisse; 2018 Jan; 14(588-589):34-38. PubMed ID: 29337446
[TBL] [Abstract][Full Text] [Related]
15. Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy.
Atkinson M; Lansdown AJ
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101635. PubMed ID: 35382989
[TBL] [Abstract][Full Text] [Related]
16. Endocrinological side-effects of immune checkpoint inhibitors.
Torino F; Corsello SM; Salvatori R
Curr Opin Oncol; 2016 Jul; 28(4):278-87. PubMed ID: 27136136
[TBL] [Abstract][Full Text] [Related]
17. Multimodality imaging of endocrine immune related adverse events: a primer for radiologists.
Alessandrino F; Shah HJ; Ramaiya NH
Clin Imaging; 2018; 50():96-103. PubMed ID: 29348053
[TBL] [Abstract][Full Text] [Related]
18. [Endocrine side effects of tumor treatment].
Braegelmann J; Führer D; Tan S
Inn Med (Heidelb); 2024 Jul; 65(7):681-689. PubMed ID: 38874811
[TBL] [Abstract][Full Text] [Related]
19. Endocrine dysfunction induced by immune checkpoint inhibitors.
Deligiannis NG; Sosa S; Danilowicz K; Rizzo LFL
Medicina (B Aires); 2021; 81(2):269-278. PubMed ID: 33906146
[TBL] [Abstract][Full Text] [Related]
20. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
